-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Street Calls of the Week
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Raised to $52 at Baird
-
-
-
-
-
-
-
CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVYâ„¢ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
-
-
-
-
-
-
-
CRISPR Therapeutics (CRSP) PT Lowered to $189 at Goldman Sachs, Following Earnings
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

